| Breakdown | TTM | Dec 2024 | Dec 2023 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 4.31B | 1.92B | 228.94M |
| Gross Profit | 3.18B | 1.42B | 160.16M |
| EBITDA | 2.21B | 480.04M | -426.43M |
| Net Income | -766.65M | -863.45M | -593.75M |
Balance Sheet | |||
| Total Assets | 32.91B | 17.83B | 4.98B |
| Cash, Cash Equivalents and Short-Term Investments | 1.94B | 1.36B | 219.51M |
| Total Debt | 18.81B | 10.62B | 2.00B |
| Total Liabilities | 29.03B | 18.25B | 5.57B |
| Stockholders Equity | 3.88B | -413.60M | -596.59M |
Cash Flow | |||
| Free Cash Flow | -8.06B | -5.95B | -1.11B |
| Operating Cash Flow | 1.69B | 2.75B | 1.83B |
| Investing Cash Flow | -9.81B | -8.66B | -3.15B |
| Financing Cash Flow | 9.17B | 7.46B | 1.79B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $3.42T | 32.72 | 32.24% | 0.71% | 15.59% | 15.89% | |
73 Outperform | $4.83B | 21.41 | ― | ― | 14.20% | 204.86% | |
66 Neutral | $549.03B | 35.91 | 70.60% | 1.00% | 11.08% | 29.56% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
54 Neutral | $71.99B | -52.13 | -53.32% | ― | 28.48% | -19.12% | |
47 Neutral | $50.44B | -55.69 | -29.17% | ― | 235.40% | 19.90% | |
46 Neutral | $27.38B | 118.61 | 3.45% | ― | -87.55% | 336.73% |
On December 31, 2025, CoreWeave, Inc. and its subsidiaries amended their DDTL 3.0 Credit Agreement and related Parent Guarantee and Pledge Agreement with MUFG Bank and associated agents to realign the financing facility with the timing of deliveries discussed on CoreWeave’s September 30, 2025 quarter earnings call. The First Amendment reduces the minimum liquidity requirement to $100 million for monthly payment dates between March 1 and May 1, 2026, delays the initial testing of the debt service coverage ratio covenant to October 31, 2027 and the contract realization ratio covenant to February 28, 2026, and allows unlimited equity cures for covenant breaches until October 28, 2026 (with limited use thereafter), effectively providing CoreWeave with greater financial flexibility and covenant headroom as it manages its growth and contractual commitments.
The most recent analyst rating on (CRWV) stock is a Hold with a $89.00 price target. To see the full list of analyst forecasts on CoreWeave stock, see the CRWV Stock Forecast page.
On December 11, 2025, CoreWeave completed a private offering of $2.587 billion in Convertible Senior Notes due 2031, which are unsecured obligations guaranteed by its subsidiaries. The proceeds, approximately $2.542 billion after expenses, will be used for capped call transactions and general corporate purposes. The offering is expected to impact CoreWeave’s market positioning by potentially reducing dilution of its Class A common stock and affecting its market price.
The most recent analyst rating on (CRWV) stock is a Hold with a $89.00 price target. To see the full list of analyst forecasts on CoreWeave stock, see the CRWV Stock Forecast page.
On October 30, 2025, CoreWeave announced the termination of its proposed merger with Core Scientific after the latter’s stockholders did not approve the merger agreement. Despite the setback, CoreWeave remains committed to its growth strategy and will continue its commercial partnership with Core Scientific, focusing on leveraging their complementary strengths.
The most recent analyst rating on (CRWV) stock is a Hold with a $140.00 price target. To see the full list of analyst forecasts on CoreWeave stock, see the CRWV Stock Forecast page.